(openPR) - Morristown, New Jersey / Munich, Germany – December 2, 2008 – Definiens, the number one Enterprise Image Intelligence™ company, has signed a co-marketing agreement with Bioscan, Inc., a leading developer of advanced imaging instrumentation for radiolabeled compounds. Under the terms of the agreement, Bioscan and Definiens will conduct cooperative marketing activities and host joint workshops and events. Customers will benefit through integrated training and implementation programs and streamlined access to the market-leading solutions offered by both companies.
Non-invasive in vivo animal imaging offers researchers a window into living biological systems. It provides the means to track a range of biological processes, from metabolism to receptors and gene-expression, and enables the effects of candidate pharmaceutical treatments to be monitored more accurately. Recent improvements in molecular imaging technologies have made in vivo preclinical imaging increasingly important to researchers, and especially to those involved in the drug development process. However, intelligent image analysis is required to extract meaningful insight from the prodigious amounts of data generated by advanced preclinical in vivo imaging systems.
Bioscan develops advanced instrumentation for the detection, synthesis and imaging of radiolabeled compounds used in life science research, molecular imaging, pharmaceutical development and nuclear medicine. The company’s dual modality NanoSPECT/CT and NanoPET/CT in vivo animal imaging systems provide unparalleled insight into molecular function at the nanoliter precision level. With these nano-nuclear imagers, Bioscan allows researchers to overcome the challenge of balancing resolution and sensitivity that has hampered the advancement of non-invasive imaging in preclinical studies.
“Definiens and Bioscan share a commitment to developing the most advanced imaging technologies on the market,” said Dr. York Hamisch, Vice President of Imaging Technologies at Bioscan. “This cooperative agreement will provide our customers with special access to Definiens’ image analysis technology, enabling them to extract information from their imagery with a high level of automation.”
Definiens provides life science organizations with software applications for analyzing and interpreting images on every scale, from cell and tissue-based assays to in-vivo imaging systems. The company’s proprietary Definiens Cognition Network Technology® is context-based, emulating human cognitive processes to extract intelligence from images of all modalities, sizes, and resolutions. Definiens image analysis software complements Bioscan’s imaging systems, enabling researchers to extract additional quantitative and anatomical information from 3D images of small animal models.
“Increased adoption of non-invasive imaging is indicative of the life science research community’s move toward a systems biology approach,” said Manfred Voglmaier, Vice President of Business Development, Life Sciences at Definiens. “Partnering with Bioscan provides an opportunity for Definiens to introduce its imaging technology to an established community of molecular imaging researchers.”
Definiens and Bioscan will continue to explore further opportunities for cooperation, which may include the co-development of user interfaces to incorporate Definiens software into Bioscan hardware. Existing Bioscan customers will also benefit from introductory offers on Definiens applications beginning in late 2008.
About Bioscan
Bioscan, Inc. is a developer and supplier of advanced molecular imaging tools for pre-clinical and biomedical research applications. Over the last two years, the company has introduced nuclear imagers with sub-mm image resolution capabilities. Developed in collaboration with Mediso Ltd of Budapest, Hungary, Bioscan’s single-photon computed tomography (SPECT) and positron emission tomography (PET) systems are the first systems that can image small animals with the same visual acuity as can be obtained from scanning humans. In addition to these dual-modality NanoPET/CT® and NanoSPECT/CT® systems, Bioscan supplies supporting radiotracer synthesis and biotracer quality control equipment allowing researchers in pharmaceutical companies and biomedical research institutes to conduct translational research and speed up the development of new therapies. Bioscan is headquartered in Washington, DC and has offices in Europe and distributors worldwide. Further information is available at www.bioscan.com
Definiens in Life Sciences
Definiens supports Life Science organizations by automating image analysis on an enterprise level, from drug discovery to diagnostics. Its image analysis software enables pharmaceutical and biomedical companies to interpret vast numbers of digital images accurately and consistently. Definiens applications improve the measurement of cell assays, the examination of tissue samples and the interpretation of non-invasive imaging, helping organizations to advance translational research and personalized medicine.
About Definiens
Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale, from microscopic cell structures to satellite images. The Definiens Cognition Network Technology®, developed by Nobel Laureate Prof. Gerd Binnig and his team, is an advanced and robust context-based technology designed to fulfill the image analysis requirements of the Medical, Life Science, and Earth Science markets. The technology is modeled on the powerful human cognitive perception processes to extract intelligence from images. Definiens provides organizations with faster image analysis results, allowing deeper insights enabling better business decisions. The company is headquartered in Munich, Germany and has offices in the United States. Further information is available at www.definiens.com.
Definiens, Definiens Cellenger, Definiens Cognition Network Technology, Definiens eCognition, Enterprise Image Intelligence and Understanding Images are trademarks or registered trademarks of Definiens.
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
Newsfeed
